El-Rakabawy Omar M, Elkholy Amal A, Mahfouz Amr A, Abdelsalam Mona M, El Wakeel Lamia M
Department of Clinical Pharmacy, Faculty of Pharmacy, October 6 University, 6 October City, 12585, Giza, Egypt.
Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Sci Rep. 2025 Aug 4;15(1):28358. doi: 10.1038/s41598-025-09783-5.
Atherosclerotic cardiovascular diseases (ASCVD) significantly contribute to global mortality, especially in type 2 diabetes mellitus (T2DM), necessitating effective preventive strategies. Curcumin is proposed to lower blood pressure, glucose level, and improve lipid profiles as an adjunctive treatment. The study aimed to assess the safety and efficacy of Curcumin supplementation on clinical outcomes and ASCVD risk of T2DM patients. Seventy-two diabetic patients with an ASCVD risk score of ≥ 5% were randomly assigned to Curcumin group (500 mg Turmeric curcumin thrice daily + conventional therapy) or Control group (conventional therapy only). Curcumin significantly reduced SBP and DBP (P ≤ 0.001 and P = 0.020, respectively) and improved ASCVD risk classification (P = 0.004). LDL-C (P = 0.024), TNF-α (P = 0.044), and MDA (P = 0.028) levels decreased, while HDL-C increased (P = 0.024) versus control. No significant differences were found between groups regarding HbA1c, FBG, TC or TG (P > 0.05). Mild adverse effects were reported, including nausea (13.9%), headache (11.1%), yellow stool (11.1%), and diarrhea (5.6%). It is concluded that Curcumin improves ASCVD risk classification, lowers SBP, DBP, LDL-C, TNF-alpha, and MDA, increases HDL-C, and is well tolerated with minor adverse effects, without impacting on BMI, HR, HbA1c, FBG, TC, or TG.
动脉粥样硬化性心血管疾病（ASCVD）是全球死亡率的重要因素，尤其是在2型糖尿病（T2DM）患者中，因此需要有效的预防策略。姜黄素被提议作为辅助治疗手段来降低血压、血糖水平并改善血脂状况。本研究旨在评估补充姜黄素对T2DM患者临床结局和ASCVD风险的安全性和有效性。72名ASCVD风险评分≥5%的糖尿病患者被随机分为姜黄素组（每日三次服用500毫克姜黄姜黄素+常规治疗）或对照组（仅接受常规治疗）。姜黄素显著降低收缩压和舒张压（分别为P≤0.001和P=0.020），并改善了ASCVD风险分类（P=0.004）。与对照组相比，低密度脂蛋白胆固醇（LDL-C，P=0.024）、肿瘤坏死因子-α（TNF-α，P=0.044）和丙二醛（MDA，P=0.028）水平降低，而高密度脂蛋白胆固醇（HDL-C，P=0.024）升高。两组在糖化血红蛋白（HbA1c）、空腹血糖（FBG）、总胆固醇（TC）或甘油三酯（TG）方面未发现显著差异（P>0.05）。报告了轻度不良反应，包括恶心（13.9%）、头痛（11.1%）、黄色大便（11.1%）和腹泻（5.6%）。结论是，姜黄素可改善ASCVD风险分类，降低收缩压、舒张压、LDL-C、TNF-α和MDA，升高HDL-C，耐受性良好，不良反应轻微，且不影响体重指数（BMI）、心率（HR）、HbA1c、FBG、TC或TG。
